Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 377.50
Bid: 379.00
Ask: 380.00
Change: 4.00 (1.07%)
Spread: 1.00 (0.264%)
Open: 379.00
High: 380.50
Low: 373.50
Prev. Close: 373.50
CHG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HMDS Contract award

16 Aug 2018 07:00

RNS Number : 9916X
Chemring Group PLC
16 August 2018
 

FOR IMMEDIATE RELEASE 16 AUGUST 2018

 

CHEMRING GROUP PLC

HMDS CONTRACT AWARD

 

Chemring Group PLC ("Chemring" or "the Group") is pleased to announce that its US based subsidiary Chemring Sensors and Electronic Systems ("CSES") has been awarded a $93m Indefinite Delivery Indefinite Quantity ("IDIQ") contract to refurbish and refresh the US DOD's fleet of Husky Mounted Detection Systems ("HMDS"). The enhanced fleet will include the addition of an array of new technologies that have been designed and developed by Chemring to be effective against the most challenging targets.

 

Work under this contract will be carried out at CSES's facility in Dulles, Virginia.

 

Michael Ord, Group Chief Executive of Chemring, commented:

 

"This award represents a significant development for Chemring and is the culmination of a number of years of research and development activity. It demonstrates the progress that the Group is making on its roadmap and the move to focus on our higher margin, niche market positions where the Group is best placed to generate future value." 

 

 

-ENDS-

 

 

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 833901

Chemring Group PLC

 

Andrew Jaques MHP Communications 0203 128 8100

James White

 

Cautionary statement

 

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

· Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,500 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under three strategic product segments: Countermeasures, Sensors & Electronics, and Energetic Systems

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CNTKMGMRKVRGRZG
Date   Source Headline
24th Feb 20239:07 amRNSDirector Declaration
1st Feb 202310:10 amRNSTotal Voting Rights
24th Jan 20233:09 pmRNSDirector/PDMR Shareholding
23rd Jan 20237:00 amRNSDirectorate Change
16th Jan 202310:44 amRNSNotice of AGM
9th Jan 20237:10 amRNSDirector Declaration
3rd Jan 202310:54 amRNSTotal Voting Rights
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20223:41 pmRNSBlock listing Interim Review
14th Dec 202212:31 pmRNSDirector/PDMR Shareholding
14th Dec 202212:28 pmRNSDirector/PDMR Shareholding
14th Dec 202212:27 pmRNSDirector/PDMR Shareholding
14th Dec 202212:25 pmRNSDirector/PDMR Shareholding
14th Dec 202212:23 pmRNSDirector/PDMR Shareholding
14th Dec 202212:20 pmRNSDirector/PDMR Shareholding
13th Dec 20227:00 amRNSFinal Results
1st Dec 202210:01 amRNSTotal Voting Rights
11th Nov 20222:30 pmRNSHolding(s) in Company
1st Nov 202210:02 amRNSTotal Voting Rights
18th Oct 20224:17 pmRNSHolding(s) in Company
6th Oct 20227:00 amRNSTrading Update
3rd Oct 20221:55 pmRNSAdditional Listings
3rd Oct 20229:36 amRNSTotal Voting Rights
12th Sep 20229:00 amRNSNotice of Results
1st Sep 20229:13 amRNSTotal Voting Rights
30th Aug 20224:13 pmRNSHolding(s) in Company
25th Aug 20222:42 pmRNSHolding(s) in Company
1st Aug 20224:23 pmRNSTotal Voting Rights
11th Jul 202210:54 amRNSDirector/PDMR Shareholding
8th Jul 20221:09 pmRNSHolding(s) in Company
5th Jul 20229:22 amRNSHolding(s) in Company
1st Jul 20229:35 amRNSTotal Voting Rights
1st Jul 20227:00 amRNSClosure of SFO investigation
28th Jun 20225:22 pmRNSDirector/PDMR Shareholding
20th Jun 20224:54 pmRNSBlock listing Interim Review
20th Jun 20224:46 pmRNSBlock listing update
8th Jun 20227:00 amRNSINTERIM RESULTS
1st Jun 202210:07 amRNSTotal Voting Rights
9th May 202211:55 amRNSTotal Voting Rights
19th Apr 20222:00 pmRNSHolding(s) in Company
6th Apr 20227:19 amRNSDirector Declaration
1st Apr 202210:00 amRNSTotal Voting Rights
28th Mar 20228:12 amRNSDirector Declaration
23rd Mar 20222:31 pmRNSDirector/PDMR Shareholding
23rd Mar 202210:50 amRNSDirector/PDMR Shareholding
23rd Mar 202210:47 amRNSDirector/PDMR Shareholding
23rd Mar 202210:46 amRNSDirector/PDMR Shareholding
15th Mar 202210:33 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.